Pivotal Therapeutics receives CDN $1.65 million in debt financing; Company closes equity portion of financing; over CDN $4.3 ...
08 10월 2013 - 5:39AM
OTC Markets
Pivotal Therapeutics receives CDN $1.65 million in debt financing;
Company closes equity portion of financing; over CDN $4.3 million
received from Crossover to date
#ReleaseContent TABLE
{
BORDER-COLLAPSE: collapse
}
TR.cnwUnderlinedCell TD
{
BORDER-BOTTOM: #000000 1px solid
}
TR.cnwDoubleUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px double
}
TR.cnwBoldUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px solid
}
TD.cnwUnderlinedCell
{
BORDER-BOTTOM: #000000 1px solid
}
TD.cnwDoubleUnderlinedCell
{
BORDER-BOTTOM: #000000 3px double
}
TD.cnwBoldUnderlinedCell
{
BORDER-BOTTOM: #000000 3px solid
}
#ReleaseContent TABLE.cnwBorderedTable TD
{
BORDER-RIGHT: black 1px solid;
PADDING-RIGHT: 2px;
BORDER-TOP: black 1px solid;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
BORDER-LEFT: black 1px solid;
PADDING-TOP: 2px;
BORDER-BOTTOM: black 1px solid;
BORDER-COLLAPSE: collapse
}
#ReleaseContent TABLE TD
{
PADDING-RIGHT: 2px;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
PADDING-TOP: 2px
}
Pivotal Therapeutics receives CDN $1.65 million in debt financing;
Company closes equity portion of financing; over CDN $4.3 million
received from Crossover to date
PR Newswire
WOODBRIDGE, ON, Oct. 7, 2013
WOODBRIDGE, ON, Oct. 7, 2013 /PRNewswire/ - Pivotal
Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty
pharmaceutical company with a focus on Omega-3 therapies
for cardiovascular disease (CVD) and overall health, announced
today
that it completed the sale of 1,649 units at a price of CDN
$1,000 per
unit of its previously announced debt financing agreement led
by
Crossover Healthcare Fund LLC, a U.S. institutional fund. Proceeds
of
the first tranche totaled CDN $1,649,280. To date the total investment
from Crossover Healthcare Fund has exceeded CDN $4,300,000.
Each unit will consist of CDN $1,000
of Convertible Promissory Notes
(the "Note" or "Notes") and warrants to purchase 1,200 shares of
common
stock of the Company (the "Warrants"). The maturity of the Notes is
two
(2) years from the date of issuance. Investors may convert their
Notes
into common shares for CDN $0.25 per
share at anytime prior to
maturity. The Notes will accrue interest at a rate of 8% per
annum.
The closing of the debt financing is subject to the satisfaction
of
customary closing conditions and is expected to occur on or
about
October 31, 2013.
The Company also announced that it closed the equity portion of
the
financing led by Crossover Healthcare Fund consisting of
12,462,768
units at a price of CDN $0.22 per
unit for total proceeds of CDN
$2,741,809. Each unit consists of one
common share and one-half
purchase warrant. Each full purchase warrant may be exercised
to
purchase one common share of the Company upon payment of the
exercise
price of $0.30 per common share. The
purchase warrants expire 60 months
following the closing of the equity portion of the private
placement
and may be called by the Company at any time after six months
following
closing, provided the common shares of the Company have traded at
a
price of at least $0.45 for 20
trading days within a 30 consecutive day
trading period.
The proceeds from the financing are being used to expand sales
and
marketing, advance ongoing clinical trials, and for general
working
capital, including business development.
Please refer to the Company Form 9 Filings on the CNSX website
(www.cnsx.ca) for detailed updates with regards to the
financing.
About VASCAZEN®
VASCAZEN® is currently available in the U.S. as a
prescription only Medical Food
specifically formulated for the dietary management of an
Omega-3
deficiency in cardiovascular patients. VASCAZEN®
is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty
acid
formulation, protected by a series of both U.S. and foreign
patents. .
VASCAZEN® has been clinically shown to correct an
Omega-3 deficiency within eight
weeks of treatment with positive concomitant effects on the
lipid
profiles, mainly a 48% reduction of triglycerides and an increase
of
HDL without negative impact on the LDL-C lipid profile.
VASCAZEN®'s results were achieved with a dose of
3 grams of EPA and DHA per day
of a prescription grade, high purity Omega-3.
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CNSX:
PVO)
specialty pharmaceutical company with a focus on cardiovascular
disease
and overall health. Pivotal Therapeutics' lead product
VASCAZEN® is a prescription only Medical Food
formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease
through
elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid
(DHA) to
levels associated with reduced risk of cardiovascular
complications. OMAZENTM is a pharmaceutical grade
Omega-3 providing over 90% pure Omega-3 in
each capsule for the maintenance of good health.
OMAZENTM is a patented product available for sale
and distribution in Canada.
Disclosure Notice
The information contained in this document is as of October 7, 2013.
This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal's actual
results
to differ materially from those projected in such
forward-looking
statements. These statements can be identified by the use of words
such
as "will", "anticipate", "estimate", "expect", "project",
"forecast",
"intend", "plan", "believe", "project", "potential", and
similar
expressions with any discussion of future operating or
financial
performance or events. In particular, factors that could cause
actual
results to differ materially from those in forward looking
statements
include the following: Pivotal's inability to obtain additional
financing on acceptable terms; growth in costs and expenses;
inability
to compete with others who provide comparable products; risk that
the
Company's products will not gain widespread market acceptance;
risks
relating to the Company's ability to maintain its CSNX listing.
Forward-looking statements speak only as of the date made and are
not
guarantees of future performance. The Company undertakes no
obligation
to publicly update or revise any forward-looking statements
contained
in this document as a result of new information or future events
or
developments. CNSX has not reviewed and does not accept
responsibility
for the adequacy or accuracy of this information.
SOURCE Pivotal Therapeutics Inc.
Pivotal Therapeutics (CE) (USOTC:PVTTF)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Pivotal Therapeutics (CE) (USOTC:PVTTF)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024